ASX:RSH

Respiri Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume1.19 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive RSH News and Ratings via Email

Sign-up to receive the latest news and ratings for Respiri and its competitors with MarketBeat's FREE daily newsletter.

About Respiri

Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include Wheezo, a mobile app, which has asthma management diary, medication usage and reminders, and symptoms and triggers to help asthma sufferers; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.

Companies Like Respiri (ASX:RSH) Are In A Position To Invest In Growth
May 17, 2021 | finance.yahoo.com

Respiri shares rise after TerryWhite Chemmart agrees to stock wheezo devices in pharmacies
April 28, 2021 | msn.com

Why the Respiri (ASX:RSH) share price shot 18% higher today
April 28, 2021 | msn.com

Respiri to launch remote patient monitoring trial in Australia
March 29, 2021 | msn.com

Why the Respiri (ASX:RSH) share price opened higher today
March 25, 2021 | msn.com

Respiri (ASX:RSH) share price on watch following FDA approval
March 22, 2021 | msn.com

Asthma costs Australia $28 billion a year. Respiri wants to change that.
March 11, 2021 | msn.com

Announcing: Respiri (ASX:RSH) Stock Soared An Exciting 307% In The Last Three Years
November 18, 2020 | finance.yahoo.com

Will the Openpay (ASX:OPY) share price reverse on positive update?
October 27, 2020 | fool.com.au

Opyl provides leading biopharma organisations access to emerging AI-assisted technologies
October 19, 2020 | proactiveinvestors.com.au

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolASX:RSH
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.respiri.co
Phone61 3 9602 3366
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$1.39 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow37.00
Book ValueA$0.01 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.13 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Respiri.

4.0 Community Rank

Outperform Votes
Respiri has received 3 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Respiri has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Respiri has received 60.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Respiri and other stocks. Vote “Outperform” if you believe RSH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RSH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Respiri does not currently pay a dividend.
Dividend Growth
Respiri does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Respiri insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$36,219.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Respiri (ASX:RSH) Frequently Asked Questions

What stocks does MarketBeat like better than Respiri?

Wall Street analysts have given Respiri a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Respiri wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Respiri's key executives?

Respiri's management team includes the following people:

Mr. Nicholas Smedley, Exec. Chairman
Mr. Marjan Mikel B.Sc., M.A.I.C.D., CEO, MD & Exec. Director
Dr. Samaneh Sarraf Shirazi, Chief Research Officer
Mr. Philippe Ludekens, Gen. Mang. of Commercial Operations
Mr. Peter Hildebrandt, Operations Mang.
Ms. Jan P. Barker, Vice-Pres of Bus. Devel.
Mr. Theo Antonopoulos, Chief Commercial Officer
Mr. Alastair Beard, Company Sec.
Prof. Noam Gavriely, Medical & Scientific Advisor
Mr. Simon Godfrey, Medical & Scientific Advisor

Who are some of Respiri's key competitors?

Some companies that are related to Respiri include 4DMedical (4DX), Adherium (ADR), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics (AMT), Analytica (ALT), AnteoTech (ADO), Anteris Technologies (AVR), Asensus Surgical (ASXC), Atomo Diagnostics (AT1), AVITA Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), CleanSpace (CSX), Cochlear (COH) and Cochlear (CHEOY).
View all of RSH's competitors.

What is Respiri's stock symbol?

Respiri trades on the ASX under the ticker symbol "RSH."

How much money does Respiri make?

Respiri has a market capitalization of $0.00 and generates $1.39 million in revenue each year.

What is Respiri's official website?

The official website for Respiri is www.respiri.co.

How can I contact Respiri?

The company can be reached via phone at 61 3 9602 3366.

This page was last updated on 9/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.